Defining candidate drug characteristics for Long-QT (LQT3) syndrome (Q1942492): Difference between revisions
From MaRDI portal
Created a new Item |
Set OpenAlex properties. |
||
(4 intermediate revisions by 3 users not shown) | |||
Property / author | |||
Property / author: Glenn Terje Lines / rank | |||
Property / author | |||
Property / author: Andrew D. McCulloch / rank | |||
Property / author | |||
Property / author: Glenn Terje Lines / rank | |||
Normal rank | |||
Property / author | |||
Property / author: Andrew D. McCulloch / rank | |||
Normal rank | |||
Property / MaRDI profile type | |||
Property / MaRDI profile type: MaRDI publication profile / rank | |||
Normal rank | |||
Property / full work available at URL | |||
Property / full work available at URL: https://doi.org/10.3934/mbe.2011.8.861 / rank | |||
Normal rank | |||
Property / OpenAlex ID | |||
Property / OpenAlex ID: W2316627542 / rank | |||
Normal rank | |||
links / mardi / name | links / mardi / name | ||
Revision as of 03:40, 20 March 2024
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Defining candidate drug characteristics for Long-QT (LQT3) syndrome |
scientific article |
Statements
Defining candidate drug characteristics for Long-QT (LQT3) syndrome (English)
0 references
19 March 2013
0 references
cardiac arrhythmias
0 references
drug design
0 references
Markov models
0 references
optimization
0 references